Clinical trial

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2026-06-30

PhasePHASE1

Study timeline

Study start (estimated)2026-06-30Date precision: day

Registry last updated2025-04-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Primary Progressive Multiple Sclerosis (PPMS)unresolved

Secondary Progressive Multiple Sclerosis (SPMS)unresolved

Non-Active Secondary Progressive Multiple Sclerosisunresolved

Non-Active SPMSunresolved

Autoimmune Diseases of the Nervous Systemunresolved

Nervous System Diseasesunresolved

Autoimmune Diseasesunresolved

Demyelinating Diseasesunresolved

Immune System Diseasesunresolved

Demyelinating Autoimmune Diseases, Central Nervous System (CNS)unresolved

Interventions

OcrelizumabDRUG · verified · RxNorm: ocrelizumab

Interleukin-2DRUG

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

FludarabineDRUG · verified · RxNorm: fludarabine

MesnaDRUG · verified · RxNorm: mesna

Sponsors & collaborators

Indapta Therapeutics, INC.lead sponsor

Mapped research locations

St LouisMissouri, United States1 OrlandoFlorida, United States1 AuroraColorado, United States1 Kansas CityKansas, United States1 StanfordCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06677710 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.